Q1. Does your trust treat myelofibrosis? If not, which other trust do you refer these patients to?
Q2.
a) Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4).
b) How many of these patients were above age 65?
Q3. How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib?
Q4.
a) How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?
b) Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with:
i. Hydroxyurea
ii. Fedratinib
iii. Received No Treatment
Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.
